1. Homepage
  2. Equities
  3. Israel
  4. TEL AVIV STOCK EXCHANGE
  5. Tikun Olam-Cannbit Pharmaceuticals Ltd
  6. News
  7. Summary
    TKUN   IL0010843675

TIKUN OLAM-CANNBIT PHARMACEUTICALS LTD

(TKUN)
End-of-day quote TEL AVIV STOCK EXCHANGE  -  05-24
2.809 ILS   -1.44%
03/30Tikun Olam-Cannbit Pharmaceuticals Ltd Reports Earnings Results for the Full Year Ended December 31, 2021
CI
2021Teva Israel and Tikun Olam-Cannbit Pharmaceuticals Ltd Signs Mutual Collaboration Agreement for Marketing and Distribution of Medical Cannabis Oil
CI
2021Tikun Olam-Cannbit Pharmaceuticals Ltd Reports Earnings Results for the Half Year Ended June 30, 2021
CI
SummaryQuotesChartsNewsCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Tikun Olam-Cannbit Pharmaceuticals Ltd announced that it expects to receive ILS 12 million in funding from Ambrosia Supherb Ltd

08/19/2021 EDT

Tikun Olam-Cannbit Pharmaceuticals Ltd announced a private placement of shares at a price of ILS 5.26 per share for gross proceeds of ILS 12,000,000 on August 19, 2021. The transaction will include participation from new investor Ambrosia Supherb Ltd. As a part of the transaction, investor will acquire 4.98% stake.


© S&P Capital IQ 2021
All news about TIKUN OLAM-CANNBIT PHARMACEUTICALS LTD
03/30Tikun Olam-Cannbit Pharmaceuticals Ltd Reports Earnings Results for the Full Year Ended..
CI
2021Teva Israel and Tikun Olam-Cannbit Pharmaceuticals Ltd Signs Mutual Collaboration Agree..
CI
2021Tikun Olam-Cannbit Pharmaceuticals Ltd Reports Earnings Results for the Half Year Ended..
CI
2021Tikun Olam-Cannbit Pharmaceuticals Ltd announced that it expects to receive ILS 12 mill..
CI
2021Tikun Olam-Cannbit Continues to Expand Its Footprint in the Pharmaceutical Arena
CI
2021Tikun Olam - Cannbit Pharmaceuticals Ltd Reports Earnings Results for the Full Year End..
CI
2021Canonic of Evogene Group and Tikun Olam-Cannbit, Sign Production and Distribution Agree..
CI
2021Tikun Olam-Cannabit and Opiostop LLC Are Establishing A JV to Conduct A Clinical Study ..
CI
2021Tikun Olam-Cannbit Develops Revolutionary System for the Characterization of Genetic Fi..
CI
2020Cannbit Pharmaceuticals Ltd announced that it expects to receive ILS 11.528 million in ..
CI
More news
Financials
Sales
Net income
Net Debt
P/E ratio
Yield
Capitalization 126 M 37,8 M 37,8 M
EV / Sales -1
EV / Sales 0
Nbr of Employees 114
Free-Float 78,8%
Chart TIKUN OLAM-CANNBIT PHARMACEUTICALS LTD
Duration : Period :
Tikun Olam-Cannbit Pharmaceuticals Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers and Directors
Ifat Kariv Chief Executive Officer & Director
Eitan Ben-Eliahu Chairman
Revital Aviram External Director
Orit Noked Independent Director
Yaron Naor Director